Micafungin - Astellas Pharma

Drug Profile

Micafungin - Astellas Pharma

Alternative Names: FK 463; Funguard; Micafungin sodium; Micamin; Mycamine

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Antifungals; Echinocandins; Lipoproteins
  • Mechanism of Action Glucan synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidaemia; Candidiasis

Most Recent Events

  • 07 Sep 2015 Launched for Aspergillosis in USA (IV) before September 2015
  • 01 Dec 2014 Astellas Pharma terminates a phase III trial in Candidiasis (In neonates, In children) in USA, Brazil, Bulgaria, Canada, Colombia, Greece, Hungary, Israel, Philippines, Romania, Turkey and Ukraine (NCT00815516)
  • 01 Sep 2013 Astellas Pharma is enrolling patients in a phase IV trial (CFDA commitment) in Candidiasis in China (NCT01982071)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top